[Comment] Endothelin Antagonism in IgA Nephropathy: Promise Ahead of Proof?

Why It Matters

Endothelin antagonism could add a disease‑modifying option for IgA nephropathy, a condition with limited targeted therapies, influencing future treatment guidelines and pharmaceutical pipelines.

Key Takeaways

• Intrarenal endothelin‑1 up‑regulation drives fibrosis in IgA nephropathy
• ALIGN phase 3 showed atrasentan slowed eGFR decline over 2.5 years
• PROTECT trial found sparsentan reduced proteinuria versus irbesartan
• Safety signals include fluid retention and edema with endothelin blockers
• KDIGO 2025 guidelines still list endothelin antagonists as investigational

Pulse Analysis

Endothelin‑1 is a potent vasoconstrictor and pro‑fibrotic peptide that is markedly elevated in the kidneys of patients with IgA nephropathy. Its interaction with the endothelin‑A receptor triggers mesangial cell proliferation, inflammation, and extracellular matrix deposition, creating a biologically plausible target for slowing disease progression. Early pre‑clinical work and small clinical cohorts suggested that blocking this pathway could preserve glomerular filtration and reduce proteinuria, prompting pharmaceutical interest in selective ERA agents.

The most compelling data to date come from the ALIGN phase‑3 trial of atrasentan, which reported a statistically significant attenuation of eGFR decline over a median 2.5‑year follow‑up, alongside modest proteinuria reductions. Parallelly, the PROTECT study demonstrated that the dual endothelin‑angiotensin receptor blocker sparsentan achieved greater proteinuria remission than standard irbesartan therapy. However, both trials flagged safety issues, particularly fluid overload and peripheral edema, underscoring the need for careful patient selection and monitoring. Meta‑analyses of renal outcomes reinforce that while ERAs improve surrogate markers, hard endpoints such as end‑stage kidney disease remain unproven.

Looking ahead, the nephrology community awaits larger, longer‑duration studies that can validate the durability of ERA benefits and clarify their place in treatment algorithms. If forthcoming evidence confirms a favorable risk‑benefit balance, ERA drugs could become a cornerstone for patients who progress despite renin‑angiotensin blockade, reshaping market dynamics and prompting guideline revisions. Until then, clinicians must weigh the promise of endothelin antagonism against the current investigational status reflected in KDIGO 2025 recommendations.